Compare Nvidia Corp (NVDA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Sana Biotechnology Inc — how do they compare? Nvidia Corp trades at $206.44 (market cap $4.92T), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Nvidia Corp is far larger — about 5630.3× Sana Biotechnology Inc's market cap, and Nvidia Corp pays a 0.49% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NVDA | SANA | |
|---|---|---|
Market Cap | $4.92T | $873.84M |
Sector | Technology | Health |
52-Week High | $235.75 | $5.92 |
52-Week Low | $165.17 | $2.68 |
Enterprise Value | $4.86T | $848.03M |
Dividend Yield | 0.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nvidia (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $1.87 exceeding the $1.76 forecast. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97%. The stock faces resistance near $210, while support holds at $201.
Outlook remains positive due to AI-driven growth and robust profitability, but risks include peak AI spending concerns and competitive pressures. Analysts project a $325.86 price target, with 75% recommending Buy. Investors should weigh high valuation multiples against sustained earnings momentum.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
